title: Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
authors.forename: Stella
authors.initials: S
authors.lastname: Marousi
authors.forename: Maria
authors.initials: M
authors.lastname: Travasarou
authors.forename: Clementine E
authors.initials: CE
authors.lastname: Karageorgiou
authors.forename: Sarah
authors.initials: S
authors.lastname: Gheuens
authors.forename: Igor J
authors.initials: IJ
authors.lastname: Koralnik
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*
chemical_list: D061067:Antibodies, Monoclonal, Humanized